408 related articles for article (PubMed ID: 29089297)
1. CCR5
Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
[TBL] [Abstract][Full Text] [Related]
2. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
Umansky V; Blattner C; Gebhardt C; Utikal J
Cancer Immunol Immunother; 2017 Aug; 66(8):1015-1023. PubMed ID: 28382399
[TBL] [Abstract][Full Text] [Related]
3. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma.
Weber R; Riester Z; Hüser L; Sticht C; Siebenmorgen A; Groth C; Hu X; Altevogt P; Utikal JS; Umansky V
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788238
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
5. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
6. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
[TBL] [Abstract][Full Text] [Related]
7. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
[TBL] [Abstract][Full Text] [Related]
8. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
9. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
[TBL] [Abstract][Full Text] [Related]
10. Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
Fleming V; Hu X; Weller C; Weber R; Groth C; Riester Z; Hüser L; Sun Q; Nagibin V; Kirschning C; Bronte V; Utikal J; Altevogt P; Umansky V
Cancer Res; 2019 Sep; 79(18):4715-4728. PubMed ID: 31337655
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
12. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
13. CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor.
Zilio S; Bicciato S; Weed D; Serafini P
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064009
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells Alleviate Renal Fibrosis Progression
Qiu Y; Cao Y; Tu G; Li J; Su Y; Fang F; Zhang X; Cang J; Rong R; Luo Z
Front Immunol; 2021; 12():698894. PubMed ID: 34566958
[TBL] [Abstract][Full Text] [Related]
15. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer.
Yang L; Wang B; Qin J; Zhou H; Majumdar APN; Peng F
Immunopharmacol Immunotoxicol; 2018 Feb; 40(1):91-97. PubMed ID: 29303012
[TBL] [Abstract][Full Text] [Related]
16. CCR5/CCR5 ligand-induced myeloid-derived suppressor cells are related to the progression of endometriosis.
Guo P; Bi K; Lu Z; Wang K; Xu Y; Wu H; Cao Y; Jiang H
Reprod Biomed Online; 2019 Oct; 39(4):704-711. PubMed ID: 31427176
[TBL] [Abstract][Full Text] [Related]
17. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Li BH; Garstka MA; Li ZF
Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
[TBL] [Abstract][Full Text] [Related]
18. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
Tang Q; Jiang J; Liu J
Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
[TBL] [Abstract][Full Text] [Related]
19. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
20. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Umansky V; Sevko A
Cancer Immunol Immunother; 2012 Feb; 61(2):275-282. PubMed ID: 22120757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
